| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.05. | Kda Group Announces Results Of Shareholders' Annual General Meeting And The Settlement Of Judicial Claims | 1 | CNW | ||
| 10.04. | KDA Group Inc: KDA appoints Kirouac as chief technology officer of GTK | 1 | Stockwatch | ||
| 09.04. | Kda Group Announces The Appointment Of Martin Kirouac As Chief Technology Officer Of Its Subsidiary Groupe Technologique Kda | 1 | CNW | ||
| KDA GROUP Aktie jetzt für 0€ handeln | |||||
| 25.03. | KDA Group Inc: KDA Group closes acquisition of GTK interest | 4 | Stockwatch | ||
| 24.03. | Kda Group Announces The Acquisition Of The Minority Interest In Its Subsidiary Groupe Technologique Kda Inc. | 1 | CNW | ||
| 24.12.25 | KDA Group Inc: KDA obtains conditional TSX-V OK for GTK share purchase | 1 | Stockwatch | ||
| 22.12.25 | Kda Group Announces A Collaboration To Integrate New Clinical Alerts Into The Medherize Platform To Support The Adoption Of Next-generation Sequencing For Breast Cancer Patients | 1 | CNW | ||
| 03.12.25 | Kda Group Announces Partnership Agreement With Chu De Québec-université Laval For The Deployment Of Medherize | 1 | CNW | ||
| 01.12.25 | Kda Group Deploys Medherize Across Community Pharmacies: A Major Step Forward In The Management Of Oral Anticancer Therapies | 1 | CNW | ||
| 26.11.25 | KDA Group To Acquire 20% Stake In Subsidiary GTK From ERxpert | 1 | RTTNews | ||
| 26.11.25 | KDA Group Inc: KDA Group to acquire 20% of ERxpert subsidiary | 2 | Stockwatch | ||
| 25.11.25 | Kda Group Announces Agreement To Acquire Minority Interest In Its Subsidiary Groupe Technologique Kda Inc. | 1 | CNW |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS MEDICAL CARE | 37,260 | -3,89 % | Dividendenbekanntmachungen (22.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 3M COMPANY US88579Y1010 0,78 USD 0,6712 EUR ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,0645 EUR ADVANCED ENERGY INDUSTRIES... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 26,280 | +1,00 % | Bodenbildung, Turnaround und Absturz - American Atomics, Dermapharm, Carl Zeiss Meditec | Der DAX schloss die Vorwoche tief im Minus ab, konnte die Woche aber am gestrigen Montag deutlich freundlicher starten. Belastend wirkten sich zuletzt der Margendruck bei deutschen Industrietiteln,... ► Artikel lesen | |
| UNITEDHEALTH | 334,40 | -0,12 % | Opening Bell: Öl, Nvidia, Meta, NextEra Energy, Dominion Energy, ServiceNow, Baidu, UnitedHealth | Die US-Börsen haben den Freitagshandel mit deutlichen Verlusten beendet. Der Dow Jones startete leicht schwächer in den Tag, baute seine Abschläge im weiteren Verlauf aus und ging schließlich 1,07 Prozent... ► Artikel lesen | |
| HIMS & HERS HEALTH | 20,220 | -1,08 % | Countdown: 24. Mai, Las Vegas: Analysten sehen bei dieser Nasdaq-Aktie über 172% Kurschance - was steckt dahinter? | ||
| BICO GROUP | 1,736 | +0,58 % | BICO Group AB: Bulletin from the Annual General Meeting in BICO Group AB (publ) | The following resolutions were passed at the Annual General Meeting (the "AGM") of BICO Group AB (publ) ("BICO" or the "Company") held today on 7 May 2026 in Gothenburg, Sweden.
Adoption of Income Statement... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,012 | -15,49 % | NuGen Medical Devices Inc.: NuGen Files Patent for Ready-to-Fill COP/COC Needle-Free Injection Nozzle, Advancing Prefilled Nozzle Technology | Toronto, Ontario--(Newsfile Corp. - March 25, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen"), a leader in needle-free drug delivery, today announced the filing of a new patent covering... ► Artikel lesen | |
| UNIDOC HEALTH | 0,062 | -7,14 % | UniDoc Health Corp.: UniDoc Reflects on Successes One Year After AMD Telemedicine Software Purchase | AMD Telemedicine software and related systems now fully integrated; UniDoc Connect used at more than 800 sites across 48 countries VANCOUVER, BC / ACCESS Newswire / May 21, 2026 / UniDoc Health Corp.... ► Artikel lesen | |
| VERU | 2,350 | 0,00 % | Veru Inc.: Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress | --Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for interim analysis first quarter calendar year 2027- --Company to host conference call and... ► Artikel lesen | |
| BONESUPPORT | 23,300 | +0,26 % | Bonesupport Holding AB: BONESUPPORT HOLDING AB (publ) - publishes Q1 2026 interim report | BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first quarter 2026.
"Solid start to 2026 - strong growth... ► Artikel lesen | |
| CLARIANE | 4,052 | -0,34 % | Clariane: Minutes of the General Meeting of 12 May 2026 | Minutes of the General Meeting of 12 May 2026 Paris, 12 May 2026 - The Annual General Meeting of shareholders of Clariane (CLARI - ISIN: FR0010386334) was held on 12 May 2026 (the « General Meeting... ► Artikel lesen | |
| VIROMED MEDICAL | 6,350 | -2,31 % | EQS-News: Viromed Medical AG schließt exklusive Vertriebskooperation mit NEBU-TEC für PulmoPlas mit Fokus auf veterinärmedizinische Anwendungen | EQS-News: Viromed Medical AG
/ Schlagwort(e): Kooperation
Viromed Medical AG schließt exklusive Vertriebskooperation mit NEBU-TEC für PulmoPlas mit Fokus auf veterinärmedizinische... ► Artikel lesen | |
| SENSEONICS | 5,500 | +0,92 % | Senseonics Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| BEYOND AIR | 0,401 | 0,00 % | Beyond Air: Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026 | Updated AACR poster data show continued survival follow-up in heavily pre- treated patients following a single intratumoral UNO injection Received US patent allowance covering proprietary gas delivery... ► Artikel lesen | |
| M3 INC | 7,800 | +1,75 % | M3, Inc. Reports Increase In Full Year Profit | TOKYO (dpa-AFX) - M3, Inc. (4YC.F) reported earnings for its full year that Increased, from last yearThe company's bottom line came in at JPY49.100 billion, or JPY72.50 per share. This compares... ► Artikel lesen | |
| NANALYSIS SCIENTIFIC | 0,092 | +6,99 % | Nanalysis Scientific Corp.: Nanalysis Announces First Quarter 2026 Results | Reports Quarterly Revenue of $10.7 Million and Adjusted EBITDA of $292 Thousand
CALGARY, AB, May 20, 2026 /PRNewswire/ - Nanalysis Scientific Corp. ("the Company"... ► Artikel lesen |